在老年人群中增加CYP2C19介导的药物相互作用风险与埃斯基塔洛普拉姆
Seonyoung Byoun1, Dong-Gyu Heo2, Minsoo Lee1
1College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.
Frontiers in pharmacology
|January 21, 2026
概括
服用埃斯基塔洛普拉姆 (S-CIT) 的老年人由于CYP2C19遗传变异而面临更高的药物相互作用 (DDI) 风险. 基于CYP2C19表型的量身定制的剂量策略被提议用于改善这种人群中的药物安全性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
- 遗传学 是一个遗传学.
背景情况:
- 埃斯基塔洛普拉姆 (S-CIT) 经常用于老年人的抑郁症和焦虑症.
- CYP2C19的遗传变异显著影响S-CIT的药理动力学,与年轻人相比,老年人的效果更为明显.
- 在服用S-CIT时,老年人可能面临CYP2C19介导的药物相互作用 (DDI) 的风险增加.
研究的目的:
- 量化比较老年人与年轻人的S-CIT中介CYP2C19DDI风险.
- 调查CYP2C19表型对老年人S-CIT DDI风险的影响.
主要方法:
- 使用基于生理学的药理动力学 (PBPK) 模型进行定量比较.
- 模拟S-CIT与四种常见的CYP2C19抑制剂同时使用:欧梅普拉,欧梅普拉,弗卢科纳和弗卢克塞丁.
- 通过分析2019年韩国国家医疗保险服务高级队列数据库,以确定联合使用的流行率来进行知情的抑制剂选择.
主要成果:
- 与年轻人相比,PBPK模型模拟预测了老年人S-CIT的DDI程度更大.
- 发现S-CIT DDI的风险在不同的CYP2C19表型 (广泛,中间和差代谢者) 上有显著差异.
结论:
- 老年人表现出与S-CIT相关的CYP2C19介导的DDI的风险较高.
- 建议针对老年人的CYP2C19表型导向S-CIT剂量策略.
- 这些策略的实施可能会减少对处方S-CIT的老年患者的药物滥用和不良事件.
相关概念视频
01:15Drug Dosing: Geriatric Patients
229
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
229
01:25Pharmacokinetics: Drug–Drug Interactions
384
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
384
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
234
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
234
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
199
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
199
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
243
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
243
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
230
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
230